Skip to main content

Jahr Robert Charles's Form 4 filing

Outlook Therapeutics, Inc. (OTLK) · filed Aug 14, 2026

Accession no.
0001104659-26-097406
Filed
Aug 14, 2026, 8:57 PM ET
Trade date
Aug 14, 2026
Filing delay
Same day
Rule 10b5-1 plan
Not checked

This filing lists 1 non-derivative transaction and 1 derivative transaction. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Jahr Robert CharlesCIK 0002076177Director, Officer (Chief Executive Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 14, 2026Common StockPPurchaseAcquired+151,515–F1–151,515Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 14, 2026Common StockPPurchaseAcquired+151,515–F1–151,515Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

On August 14, 2026, the reporting person acquired 151,515 shares of common stock and accompanying warrants to purchase 151,515 shares of common stock in the Issuer's underwritten public offering of shares of common stock and accompanying warrants for a combined public offering price of $0.99 per share of common stock and accompanying warrant.

Referenced by the price of 1 transaction in Table I and 1 transaction in Table II.

Read the full filing on SEC EDGAR (opens in a new tab)